Page last updated: 2024-11-11

epostane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID6917713
CHEMBL ID2106218
SCHEMBL ID8577627
MeSH IDM0135564

Synonyms (26)

Synonym
win 32729
epostanum [latin]
4,5-epoxy-3,17-dihydroxy-4,17-dimethylandrost-2-ene-2-carbonitrile (4alpha,5alpha,17beta)
epostano [spanish]
androst-2-ene-2-carbonitrile, 4,5-epoxy-3,17-dihydroxy-4,17-dimethyl-, (4alpha,5alpha,17beta)-
win-32729
epostane
80471-63-2
epostano
epostane [usan:inn:ban]
unii-6375t36951
win 32,729
6375t36951 ,
epostanum
androst-2-ene-2-carbonitrile, 4,5-epoxy-3,17-dihydroxy-4,17-dimethyl-, (4.alpha.,5.apha.,17.beta.)-
4alpha,5-epoxy-3,17beta-dihydroxy-4,17-dimethyl-5alpha-androst-2-ene-2-carbonitrile
epostane [mi]
epostane [usan]
epostane [inn]
epostane [mart.]
4,5-epoxy-3,17-dihydroxy-4,17-dimethylandrost-2-ene-2-carbonitri
CHEMBL2106218
CETKWEWBSMKADK-GSXVSZIWSA-N
SCHEMBL8577627
Q15633977
(1s,2r,6r,8s,11s,12s,15s,16s)-5,15-dihydroxy-2,6,15,16-tetramethyl-7-oxapentacyclo[9.7.0.02,8.06,8.012,16]octadec-4-ene-4-carbonitrile

Research Excerpts

Overview

Epostane is a synthetic 17 alpha-alkylated 5 beta-androstane derivative, active following oral administration and devoid of any apparent androgenic, estrogenic or antiestrogenic potency. It is a competitive inhibitor of the 3-beta hydroxysteroid dehydrogenase enzyme system.

ExcerptReferenceRelevance
"Epostane is a synthetic 17 alpha-alkylated 5 beta-androstane derivative, active following oral administration and devoid of any apparent androgenic, estrogenic or antiestrogenic potency. "( Plasma protein changes induced by two orally administered androgen derivatives.
Carlström, K; Doeberl, A; Laurell, CB; Rannevik, G, 1996
)
1.74
"Epostane is a competitive inhibitor of the 3-beta hydroxysteroid dehydrogenase enzyme system."( Induction of abortion in early first trimester human pregnancy using epostane.
Gillmer, MD; Webster, MA, 1989
)
1.13
"Epostane is a steroid which inhibits the synthesis of progesterone by inhibiting the enzyme 3-beta-hydroxysteroid dehydrogenase. "( Antiprogestins.
Crooij, MS, 1988
)
1.72

Treatment

ExcerptReferenceRelevance
"Epostane treatment also caused a significant reduction in peripheral FSH concentrations and an increase in mean LH concentration."( 3 beta-hydroxysteroid dehydrogenase inhibitor reduces ovarian steroid production but increases ovulation rate in the ewe: interactions with gonadotrophins and inhibin.
Baxter, G; McBride, D; McNeilly, AS; Webb, R, 1992
)
1

Pharmacokinetics

ExcerptReferenceRelevance
" According to concentration versus time data, the pharmacokinetic model of epostane in all rats followed a pattern of one-compartment model."( [Pharmacokinetics of epostane in rats].
Han, Q; Li, D; Li, QY; Liu, CG; Liu, X; Yang, XY, 1993
)
0.84

Dosage Studied

ExcerptRelevanceReference
" Abortion occurred in 21 women (70%) in the lower dosage group and in 20 women (87%) in the higher dosage group."( Induction of abortion in early first trimester human pregnancy using epostane.
Gillmer, MD; Webster, MA, 1989
)
0.51
" The higher abortion rate recorded in the higher-dose group may be a dose-response effect; alternatively, it may be due to a more constant inhibition of the hydroxysteroid dehydrogenase enzyme system."( Induction of abortion in early first trimester human pregnancy using epostane.
Gillmer, MD; Webster, MA, 1989
)
0.51
" Plasma protein binding of epostane was determined by equilibrant dialysis of the plasma of rats given the drug and found that the degree of binding was not correlated with drug dosage under our experimental conditions."( [Pharmacokinetics of epostane in rats].
Han, Q; Li, D; Li, QY; Liu, CG; Liu, X; Yang, XY, 1993
)
0.9
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (70)

TimeframeStudies, This Drug (%)All Drugs %
pre-199036 (51.43)18.7374
1990's18 (25.71)18.2507
2000's12 (17.14)29.6817
2010's4 (5.71)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.92

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.92 (24.57)
Research Supply Index4.34 (2.92)
Research Growth Index4.11 (4.65)
Search Engine Demand Index33.89 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.92)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (8.57%)5.53%
Reviews3 (4.29%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other61 (87.14%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]